Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Organogenesis ORG -- Ignore unavailable to you. Want to Upgrade?

To: JMood who wrote (1182)	1/29/1999 10:53:00 AM
From: Link Lady	Read Replies (1) \| Respond to of 1223

quicken.excite.com AIA to Release Results of Investor Survey Thursday, January 28, 1999 09:31 AM Mail this article to a friend new! DENVER--(BUSINESS WIRE)--Jan. 28, 1999--The Association for Investor Assistance (AIA) conducts research on Investor Relations (IR) departments of publicly traded companies. This no-charge service is extremely beneficial to the investing public. With the continuing emergence of electronic commerce in the financial industry, the individual investor is beginning to make technical decisions that were previously handled by licensed stockbrokers. In order to succeed in the financial markets of the twenty-first century, individual investors will need the same caliber of information that institutions and major brokerage firms rely on to conduct business. The IR officers of publicly traded companies are critical conduits of this information. The AIA is researching hundreds of companies on an ongoing basis. The central component of that research is a blind audit, which includes contacting the Investor Relations Department of a particular company to determine their efficiency, expediency, and the overall tone of the organization. In short, personal contact with the IR department can be similar to taking the pulse of the corporation in that it offers some perspective on how the company runs internally. Additionally, the AIA welcomes and encourages direct feedback from investors regarding their satisfaction with the company's performance. The Association for Investor Assistance is a no-charge consumer service located at www.investoraware.org. The AIA is currently soliciting input on the companies listed below. AC MOORE ARTS & CRAFTS INC (Nasdaq: ACMR), TECO ENERGY INC (NYSE: TE), UNIONBANCAL CORP (Nasdaq: UNBC), SUNBEAM CORP NEW (NYSE: SOC), DAVOX CORP (Nasdaq: DAVX), SCHLUMBERGER LTD (NYSE: SLB), H J HEINZ CO (NYSE: HNZ), MILLENNIUM CHEMICALS INC (NYSE: MCH), FORTE SOFTWARE INC (Nasdaq: FRTE), PERIPHONICS CORP (Nasdaq: PERI), STEELCASE INC (NYSE: SCS), CONSECO INC (NYSE: CNC), ECSOFT GROUP PLC (Nasdaq: ECSGY), TRIGON HEALTHCARE INC (NYSE: TGH), TRANSKARYOTIC THERAPIES INC (Nasdaq: TKTX), ORGANOGENESIS INC (AMEX: ORG), UNITRIN (Nasdaq: UNIT), UNIPHASE CORP (Nasdaq: UNPH), ZYMETX INC (Nasdaq: ZMTX) Investor input is stored for approximately twenty-four hours at www.investoraware.org. The research department then analyzes and compiles this data into reports made available at the site. The Association for Investor Assistance has no relationship with any publicly traded companies and the results of its surveys reflect the information provided by investors and interested parties that visit www.investoraware.org. CONTACT: The Association for Investor Assistance David Cooper, 1-888/363-4739 Quote for referenced ticker symbols: ZMTX, UNPH, UNIT, UNBC, TKTX, TGH, TE, SOC, SLB, SCS, PERI, ORG, MCH, HNZ, FRTE, ECSGY, DAVX, CNC, ACMR © 1999, Business Wire

To: JMood who wrote (1182)	5/8/2000 4:50:00 PM
From: Bruce Cullen	Read Replies (1) \| Respond to of 1223

Monday May 8, 4:42 pm Eastern Time FDA panel backs product for diabetic foot ulcers GAITHERSBURG, Md., May 8 (Reuters) - Federal advisers on Monday backed a product made using human skin cells for helping to heal diabetic foot ulcers, wounds that are hard to treat and that can lead to amputations. The product, known as Apligraf, is manufactured by Canton, Mass.-based Organogenesis Inc. (AMEX:ORG - news). Novartis AG holds marketing rights to Apligraf, which has been sold in the U.S. market since 1998 for treating leg ulcers caused by circulatory problems. Now, the companies are asking the Food and Drug Administration to allow promotion of Apligraf for diabetic foot ulcers, which afflict between 600,000 and 800,000 U.S. diabetics each year. The FDA usually follows its panels' advice.